NYSE · Health care

IGC Pharma, Inc. (IGC)

IGC Pharma, Inc. reported revenue of $1.3M in fiscal 2025, down 5.5% from a year earlier. It posted a net loss of $7.1M. In fiscal 2025 capital spending exceeded operating cash flow by $4.9M. At June 30, 2026 it held $331K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Price

$0.28

+0.46% on the day · September 25, 2026

52-week range $0.24 to $0.45

Market cap

$29.2M

Revenue (FY2025)

$1.3M

-5.5% year on year

Net margin

-560.3%

What IGC Pharma, Inc. does

IGC Pharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker IGC.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$1.3M	-$7.4M	-$7.1M	-$0.09	-$4.9M
2024	$1.3M	-$9.8M	-$13M	-$0.22	-$5.3M
2023	$911K	-$11.6M	-$11.5M	n/a	-$7.4M
2022	$397K	-$15.4M	-$15M	n/a	-$7.7M
2021	$898K	-$8.7M	-$8.8M	-$0.21	-$12.3M
2020	$4.1M	-$6.9M	-$7.3M	-$0.19	-$13.1M

Next report expected around November 13, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 14, 2025. Not a date the company has announced. See the report calendar

Where IGC ranks in Health care

Revenue$1.3M

#560 of 646 in Health care · Bottom 13%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What IGC Pharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 14, 2026
Quarterly report 10-Q · period to June 30, 2026Revenue fell 19% to $265K versus the same quarter last year; diluted EPS -$0.03 versus -$0.02.
July 14, 2026
Investor disclosure 8-K
July 6, 2026
Material agreement 8-K
June 8, 2026
Material agreement 8-K
May 15, 2026
Quarterly report 10-Q · period to March 31, 2026Revenue fell 3.9% to $317K versus the same quarter last year; diluted EPS -$0.02 versus -$0.02.
April 20, 2026
Material agreement 8-K
March 30, 2026
Other event 8-K
March 18, 2026
Transition-period annual report 10-KT · period to December 31, 2025
March 12, 2026
Material agreement 8-K
January 6, 2026
Material agreement 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 1, 2026. Insider transactions on SEC

Insider trades

What the people running IGC Pharma, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

Bought (open market)

last 90 days

Sold

last 90 days

Date	Insider	What	Shares	Price	Value	Filing
June 30, 2026	Grimaldi ClaudiaPFO, Director	Received as pay	2,048,378	$0.27	$553.1K	Form 4
June 30, 2026	Mukunda RamCEO, Director	Received as pay	2,226,475	$0.27	$601.1K	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns IGC

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Bradbury Strategic Investment Fund A13D, may seek influence	18.3%	13,823,529	May 21, 2024

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

2 insiders reported holding 10,296,655 shares in total, about $2.9M at the last price.

Holder	Shares	As of
Mukunda RamCEO, Director	6,875,563	June 30, 2026
Grimaldi ClaudiaPFO, Director	3,421,092	June 30, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about IGC

What does IGC Pharma, Inc. do?

IGC Pharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker IGC.

Is IGC Pharma, Inc. profitable?

No. In fiscal 2025 it reported a net loss of $7.1M on revenue of $1.3M.

How much revenue does IGC Pharma, Inc. make?

In fiscal 2025 IGC Pharma, Inc. reported revenue of $1.3M. That is 5.5% less than a year earlier.

When did IGC Pharma, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026.

Similar companies

Compare IGC with

Compare IGC with any company

Follow IGC

Get an email when IGC Pharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow IGC: get an email when it files

Where the numbers come from

Financial figures are the values IGC Pharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.